RSS Feeds
Search

Companies

Companies

Displaying 1..7 of 7 - per page
Order by
Profiled on pharmalicensing.com National Jewish Health
The mission of National Jewish Health is to heal, to discover and to educate as a preeminent healthcare institution. More
Decision Resources Inc.
The worldwide leader in market research publications, advisory services and consulting More
BiotechEast Co., Ltd. (Technology Partner)
BiotechEast is a one-stop, full-service marketing consultancy for those looking to take advantage of the dynamic opportunities in Taiwan's burgeoning life science industry. More
LAWSON Business Development
LAWSON HEALTH RESEARCH INSTITUTE is one of Canada's largest hospital-based research institutes. More
Good Biotech Corporation
Good Biotech Corporation (GBC) is a leading producer of industrial scale high-purity polyclonal IgY(-Fc) antibodies from duck egg yolk, offering a wide range of biotechnology applications. More
Dragon Pharmaceuticals
Our business is the development and commercialization of recombinant human proteins for therapeutic use. More
MedicAlarm
More
Displaying 1..7 of 7 - per page
Order by

Related Reports

Market Research Reports provided by reports.iptechex.com
Diabetes Drug Discoveries 2009: what the future holds
Feb 2009 - 160 pages - $1,390
Epidemiology: Diabetes in India - a country faced with a mammoth diabetes epidemic
Mar 2011 - 43 pages - $5,700
Epidemiology: Diabetes in Australia - Despite government efforts to promote healthy lifestyles, the number of cases of diabetes in Australia is set to soar
Jun 2011 - 44 pages - $5,700
Epidemiology: Type 1 diabetes - There will be an increasing number of new cases of type 1 diabetes in the seven major markets in the coming decade
Dec 2010 - 25 pages - $5,700
Epidemiology: Diabetes in China - Aging population, rising overweight and obesity are driving the diabetes epidemic
Mar 2011 - 42 pages - $5,700
Hot Topics in Type 2 Diabetes: Complications and Comorbidities – Physician insight on diabetic complications, comorbidities and treatment
Aug 2011 - 55 pages - $5,700
Epidemiology: Type 2 Diabetes
Dec 2010 - 31 pages - $5,700
Treatment Algorithms: Type 2 Diabetes – Novel classes drive fragmentation of treatment choices in type 2 diabetes
Jul 2011 - 92 pages - $7,600
Tradjenta (linagliptin) - First Member of DPP - 4 Inhibitor Class to Be Approved by US FDA at One Dosage Strength
May 2011 - 7 pages - $500
Byetta Wave 4 Tracking Survey; Trends in Usage of Type II Diabetes Mellitus Therapeutics
Nov 2007 - $2,500
More Related Market Research Reports >>>

Your selection

Industry sector
Academic/Research del
Therapeutic target
Metabolism del
Diabetes type II del

Browse By

Industry sector
Animal health
Biotech
Diagnostic
Drug delivery
Medical device
Pharmaceutical
Geographic location
Africa
Asia
Australia/New Zealand
Central America
Europe
Near & Far East
North America
South America

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us